BIEL: The "Intel Inside" of the Electrome Revolution = Revenue Explosion!
For those still missing the big picture: Electrome is the Platform; BIEL is the Engine.
Electrome isn’t a separate "side project." It is the commercial vehicle that finally unlocks 30 years of BIEL’s clinical research. Think of it as Intel Inside—the world interacts with the software and the interface (Electrome), but the machine cannot run without the silicon (BIEL hardware).
The Strategic Shift: From Device Seller to OEM Powerhouse
The partnership transforms BIEL’s fundamental business model:
From Standalone to Infrastructure: BIEL shifts from a standalone device seller to the regulated OEM backbone of a scalable, software-layered ecosystem.
Instant Distribution: Electrome provides the "Last Mile" access BIEL lacked—onboarding clinical providers, VA partnerships, and retail channels.
Data as a Moat: Electrome’s AI-guided care models rely on BIEL’s 30 years of peer-reviewed PEMF science as their credibility backbone.
Multi-Vertical Demand: Every expansion into Sleep, Women’s Health, or Veterinary medicine creates a fresh wave of recurring hardware orders for BIEL.
The Revenue Projection: The Math Trolls Are Ignoring
Electrome’s expansion creates a compounding hardware demand. Here is the breakdown of the OEM revenue potential based on a blended $15 OEM price point per device:
Phase 1: The PAINKILLER™ Launch (Year 1)
Focus: Initial rollout across clinic, retail, and DTC channels.
Volume: 50k – 150k units.
Revenue Impact: $0.75M – $2.25M.
Phase 2: Vertical Expansion (Year 2–3)
Focus: Activation of Sleep, Recovery, and Post-Surgical verticals.
Scaling: Each new vertical adds 20–40% incremental hardware demand.
Revenue Impact: $4M – $7M.
Phase 3: National Platform Penetration
The Goal: Capturing just 1% of the U.S. chronic pain market (approx. 500k annual deployments).
Revenue Impact: $7.5M+ annually.
The Multiplier: At 2–3% market penetration, BIEL sees $15M – $22M in high-margin OEM revenue.
Conclusion
The market is currently pricing BIEL as a struggling OTC company. It should be pricing it as the exclusive, regulated hardware provider for a high-growth, AI-native therapeutics platform.
Electrome is scaling a national bioelectric medicine platform. Every single node in that network is a BIEL-manufactured device. Revenue isn't just "waking up"—it's being hard-wired into a scalable, national ecosystem.
For those still missing the big picture: Electrome is the Platform; BIEL is the Engine.
Electrome isn’t a separate "side project." It is the commercial vehicle that finally unlocks 30 years of BIEL’s clinical research. Think of it as Intel Inside—the world interacts with the software and the interface (Electrome), but the machine cannot run without the silicon (BIEL hardware).
The Strategic Shift: From Device Seller to OEM Powerhouse
The partnership transforms BIEL’s fundamental business model:
From Standalone to Infrastructure: BIEL shifts from a standalone device seller to the regulated OEM backbone of a scalable, software-layered ecosystem.
Instant Distribution: Electrome provides the "Last Mile" access BIEL lacked—onboarding clinical providers, VA partnerships, and retail channels.
Data as a Moat: Electrome’s AI-guided care models rely on BIEL’s 30 years of peer-reviewed PEMF science as their credibility backbone.
Multi-Vertical Demand: Every expansion into Sleep, Women’s Health, or Veterinary medicine creates a fresh wave of recurring hardware orders for BIEL.
The Revenue Projection: The Math Trolls Are Ignoring
Electrome’s expansion creates a compounding hardware demand. Here is the breakdown of the OEM revenue potential based on a blended $15 OEM price point per device:
Phase 1: The PAINKILLER™ Launch (Year 1)
Focus: Initial rollout across clinic, retail, and DTC channels.
Volume: 50k – 150k units.
Revenue Impact: $0.75M – $2.25M.
Phase 2: Vertical Expansion (Year 2–3)
Focus: Activation of Sleep, Recovery, and Post-Surgical verticals.
Scaling: Each new vertical adds 20–40% incremental hardware demand.
Revenue Impact: $4M – $7M.
Phase 3: National Platform Penetration
The Goal: Capturing just 1% of the U.S. chronic pain market (approx. 500k annual deployments).
Revenue Impact: $7.5M+ annually.
The Multiplier: At 2–3% market penetration, BIEL sees $15M – $22M in high-margin OEM revenue.
Conclusion
The market is currently pricing BIEL as a struggling OTC company. It should be pricing it as the exclusive, regulated hardware provider for a high-growth, AI-native therapeutics platform.
Electrome is scaling a national bioelectric medicine platform. Every single node in that network is a BIEL-manufactured device. Revenue isn't just "waking up"—it's being hard-wired into a scalable, national ecosystem.
1
